New possibilities of pharmacotherapy for systemic lupus erythematosus: Prospects for the use of anifrolumab (monoclonal antibodies to type I interferon receptor)
Systemic lupus erythematosus (SLE) is a systemic autoimmune rheumatic disease of unknown etiology, characterized by overproduction of organ-specific autoantibodies to various components of the cell nucleus and the development of immune-inflammatory damage to internal organs. According to modern conc...
Saved in:
Main Authors: | E. L. Nasonov, A. S. Avdeeva, T. V. Popkova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA PRESS LLC
2021-10-01
|
Series: | Научно-практическая ревматология |
Subjects: | |
Online Access: | https://rsp.mediar-press.net/rsp/article/view/3072 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Portrait of a patient with systemic lupus erythematosus for the prescription of the type I interferon inhibitor anifrolumab
by: T. M. Reshetnyak, et al.
Published: (2023-12-01) -
Efficacy and safety of the type I interferon receptor inhibitor anifrolumab in patients with systemic lupus erythematosus (results of a 6-month study)
by: T. M. Reshetnyak, et al.
Published: (2024-04-01) -
Experience with type I interferon inhibitor in systemic lupus erythematosus
by: Ya. A. Leineman, et al.
Published: (2022-08-01) -
Rapid achievement of low disease activity during the use of a type I interferon inhibitor in a patient with torpid systemic lupus erythematosus (case report)
by: A. A. Baranov, et al.
Published: (2024-06-01) -
Experience of using Anifrolumab in the treatment of patients with systemic lupus erythematosus
by: E. V. Bolotova, et al.
Published: (2025-03-01)